X
KYMR icon

Xponance’s Kymera Therapeutics KYMR Stock Holding History

Xponance’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$448K Buy
5,374
+869
+19% +$68.8K ﹤0.01% 1062
2025
Q4 		$351K Buy
4,505
+522
+13% +$35.3K ﹤0.01% 1093
2025
Q3 		$225K Buy
+3,983
New +$180K ﹤0.01% 1302

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Xponance's KYMR Position: Q1 2026 in Review

Xponance increased its Kymera Therapeutics (KYMR) stake by 19% in Q1 2026, buying an estimated $68.8K and bringing the position to 5,374 shares worth $448K. The position accounts for ﹤0.01% of the portfolio, ranked #1062.

Xponance first reported a position in KYMR in Q3 2025 and has held it in 3 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Xponance held 5,374 shares of Kymera Therapeutics worth $448K as of Q1 2026.
  • Xponance bought 869 Kymera Therapeutics shares in Q1 2026, an estimated $68.8K.
  • Kymera Therapeutics made up ﹤0.01% of Xponance's portfolio in Q1 2026, its #1062 holding.
  • Xponance first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.